Brought to you by 
4SC grants resminostat rights to Yakult Honsha
18 Apr 2011
Executive Summary
Japanese pharmaceutical and nutritional foods company Yakult Honsha Co. Ltd. is continuing to grow its cancer business, signing its second deal in the space this year. 4SC AG (autoimmune and oncology therapeutics) has granted Yakult exclusive rights to develop and sell its Phase II pan-histone-deacetylase (HDAC) inhibitor resminostat in Japan.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com